Last reviewed · How we verify
Comparator: Adacel™
Adacel is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis.
Adacel is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis. Used for Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in adolescents and adults.
At a glance
| Generic name | Comparator: Adacel™ |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Adacel contains inactivated toxoids of diphtheria and tetanus, acellular pertussis antigens, and inactivated poliovirus particles. When administered, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory immune cells against these four pathogens. This provides active immunization and protection against these infectious diseases.
Approved indications
- Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in adolescents and adults
Common side effects
- Injection site pain, redness, or swelling
- Headache
- Fatigue
- Muscle aches
- Fever
Key clinical trials
- Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children (PHASE2)
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) (PHASE3)
- Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults (PHASE2)
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007) (PHASE3)
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) (PHASE3)
- A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005) (PHASE3)
- Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005) (PHASE3)
- Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: Adacel™ CI brief — competitive landscape report
- Comparator: Adacel™ updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI